TLDR JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
The introduction of Janus kinase (JAK) inhibitors marked significant progress in treating alopecia areata, an autoimmune disease. Although the treatment was symptomatic and hair loss often recurred within months after stopping therapy, even patients with long-standing, therapy-resistant alopecia areata experienced notable hair regrowth. This improvement had a profoundly positive impact on patients' quality of life.
182 citations,
January 2018 in “Journal of the American Academy of Dermatology” Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.
102 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Restoring hair bulb immune privilege is crucial for managing alopecia areata.
355 citations,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
196 citations,
September 2016 in “JCI insight” Ruxolitinib effectively regrows hair in most patients with severe hair loss.
421 citations,
April 2012 in “The New England Journal of Medicine” Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
